Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Liabilities and Shareholders Equity: 2014-2024

Historic Liabilities and Shareholders Equity for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $382.9 million.

  • ImmunityBio's Liabilities and Shareholders Equity rose 42.36% to $519.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 6.20%. This contributed to the annual value of $382.9 million for FY2024, which is 24.09% down from last year.
  • As of FY2024, ImmunityBio's Liabilities and Shareholders Equity stood at $382.9 million, which was down 24.09% from $504.5 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Liabilities and Shareholders Equity ranged from a high of $504.5 million in FY2023 and a low of $221.4 million during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $382.9 million (2024), whereas its average is $416.6 million.
  • In the last 5 years, ImmunityBio's Liabilities and Shareholders Equity skyrocketed by 111.81% in 2021 and then decreased by 24.09% in 2024.
  • ImmunityBio's Liabilities and Shareholders Equity (Yearly) stood at $221.4 million in 2020, then soared by 111.81% to $468.9 million in 2021, then decreased by 22.72% to $362.4 million in 2022, then soared by 39.21% to $504.5 million in 2023, then declined by 24.09% to $382.9 million in 2024.